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A B S T R A C T
Skin melanoma is by far the most lethal skin cancer, it is unpredictable by nature and presents a severe diagnostic
problem. One of the major issues in melanoma diagnostics is to differentiate it with confidence from a dysplastic nevus.
Thus, the aim of this study was to evaluate hTERT expression on a spectrum of dermal lesions (from normal skin to pri-
mary melanoma) in order to examine its possible role as a diagnostic marker in melanoma diagnostics. In this study we
analyzed the expression of hTERT by real-time PCR on 58 freshly obtained biopsy samples (4 samples of normal skin, 12
dermal nevi, 23 dysplastic nevi, 19 primary melanomas). Our results showed slightly greater hTERT expression in
dysplastic nevi than melanomas with major data overlap. Considering the given results, hTERT does not seem to be a re-
liable diagnostic marker for melanoma.
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Introduction
Telomerase is an enzyme that synthesizes telomeric
repeat sequences (TTAGGG)n, which protects chromo-
somes from shortening that consequently leads to recom-
bination, end-to-end fusion and rearrangements1. Cells
without telomerase activity exhibit limited growth abil-
ity whereas cells showing telomerase activity are immor-
talized. Telomerase is a ribonucleoprotein complex con-
sisting of two subunits: the human telomerase RNA
(hTR), which is complementary to the telomeric single
stranded overhang and is used as a template for the syn-
thesis of TTAGGG repeats and the human telomerase re-
verse transcriptase (hTERT), catalytic protein subunit
which is responsible for the process of telomeric DNA
synthesis2. Telomerase activity is the most general mo-
lecular marker for the identification of human cancer
and can be detected in 85% of all tumors, whereas most
healthy tissues exhibit little or no telomerase expression.
The hTR is ubiquitously expressed in humans, whereas
hTERT mRNA expression is suppressed in most somatic
tissues after neonatal period3. Considering that expres-
sion of hTERT is strongly correlated with telomerase ac-
tivity in skin tumors, we decided to measure hTERT
expression4. Malignant melanoma accounts for less than
5% of all skin cancers but it is by far more lethal. The in-
cidence and mortality rates of malignant melanoma have
been rapidly increasing in the last decade5,6.
The most difficult issue in the melanoma diagnostics
is clear differentiation between melanoma and a dys-
plastic nevus. There are no clear guidelines to recognize
dysplastic nevi that show most potential towards malig-
nant transformation. Furthermore, there is a need for a
more detailed prognosis and follow-up management.
In this study we evaluated the expression of hTERT
mRNA on a freshly obtained dermal tissue using real-
-time PCR. We attempted to examine expression levels
between dermal, dysplastic nevi and malignant mela-
noma showing different Clark-Breslow staging and asso-
ciate them with pathohistological diagnostic/prognostic
parameters.
1401
Received for publication July 12, 2010
Materials and Methods
Patients and tissues
In total, 58 freshly obtained samples (4 normal skin,
12 dermal nevi, 23 dysplastic nevi, 19 primary melano-
mas) were examined for hTERT mRNA expression. Sam-
ples were obtained from the patients that were admitted
to the Department of Surgery, Rijeka University Hospital
Center, for lesion removal and were diagnosed at the De-
partment of Pathology, School of Medicine, University of
Rijeka, in 2009. All patients were informed about proce-
dures to be conducted and upon understanding and agre-
eing they signed a written consent. Excised biopsy sam-
ples were immediately immersed and stored in RNA later
(Takara Bio inc., Otsu, Shiga, Japan) and were subse-
quently taken to the dermatopathologist for microscopic
evaluation. The dermatopathologist first inspected ex-
cised samples on a snap frozen section and determined if
there was enough material to perform routine diagnos-
tics and conduct a study. A small portion of designated
samples selected for the RNA isolation were stored in
RNA later at –30oC for two weeks until the patients were
given the complete diagnosis.
RNA isolation
Tissue samples were homogenized in MagNA Lyser
(Roche, Basel, Switzerland) and RNA was isolated ac-
cording to the manufacturer instructions using Nucleo-
spin RNA isolation kit (Machery-Nagel, Düren, Ger-
many). Purity of RNA was evaluated using Cary 100
UV-Vis spectrophotometer (Varian Inc, USA). Only sam-
ples with 260/280 nm ratio between 1,6–1,9 were used for
further analysis.
cDNA synthesis
Isolated RNA (0,8–1,2 mg) was supplemented with
DEPC treated H20 to reach the final volume of 8mL.
PrimeScript Reverse transcriptase Kit(Takara Bio inc.,
Otsu, Japan) was used for reverse transcription. Oligo
dT primers were selected to eliminate unnecessary ribo-
somal RNA and cDNA was scanned on Cary 100 UV-Vis
spectrophotometer(Varian Inc., Palo Alto, USA) to get
the final concentration of the material used in the real
time PCR reaction.
Real time quantitative PCR
Quantitative, real-time PCR has been described ear-
lier by Heid et al.7. Briefly, 2mL of cDNA was used for
both hTERT and b-2-microglobulin (reference gene) ex-
pression measurement in tissue samples. Standard cur-
ves which were made for hTERT and b-2-microglobulin
(Figure 1) showed efficiency under 1.9 and error under
0.25 which was the prerequisite for further data analysis.
Reactions were run on a LightCycler 1.5 Instrument
(Roche, Basel, Switzerland) with LightCyclerSoftware
4.05 using four step cycling program that consisted of the
following: 1) Denaturation-1cycle; 2) Amplification 45
cycles 95oC-10sec, 55oC-20 sec, 72oC-20 sec. Sybr Green
Premix Ex Taq (Takara Bio inc., Otsu, Shiga, Japan) was
used for real time PCR reaction. Primers for hTERT can
be found in Primer Bank (PrimerBank ID 22759946a2).
Sensors collected emission spectra of all samples on
530nm channel during the last 20 seconds of the primer
annealing/elongation step. The reaction was set to 40 cy-
cles after which melting point analysis and relative quan-
tification were made.
Results
The level of expression of hTERT is presented in Ta-
ble 1. Expression of hTERT was identified in almost all
samples. All nevi showed hTERT expression but also 4
out of 12 samples of normal skin. The normal skin which
was used as a control was non UV-irradiated. The expres-
sion level varied between samples but nevertheless it
showed distinct pattern. In general, dermal nevi showed
M. Katunari} et al.: hTERT in Primary Melanoma Biopsies, Coll. Antropol. 34 (2010) 4: 1401–1404
1402
Fig. 1: A) b-2microglobulin standard curve (Error: 0.195 Effi-
ciency: 1.818); B) hTERT standard curve (Error: 0.232, Efficiency:
1.827). TA – Telomerase Activity, b2M – b-2-microglobulin.
TABLE 1





Normal skin 0.92x10 ±0.235
Dermal nevi 81x102 ±3.25x102
Dysplastic nevi 22x104 1.25x104
Primary melanoma 92x103 2.57x103
expression similar to the expression of normal skin while
dysplastic and melanocytic lesions showed elevated ex-
pression. To our surprise, hTERT levels in dysplastic
nevi were somewhat higher than those measured in
melanocytic lesions.
Discussion
Major problems in melanoma diagnostics are dys-
plastic nevus management and progression evaluation. It
is mainly due the fact that malignant melanoma has
shown to have large heterogeneity in molecular patho-
genesis. Several studies have tried to establish molecular
markers as prognostic and/or diagnostic markers in ma-
lignant melanoma. Most markers were connected with
dysregulated growth factor signaling and tyrosine kinase
inhibitors8. However, none of them showed to be valid
and reliable.
TA (telomerase activity) has been detected in almost
all human cancers, including breast, ovary, bladder pros-
tate, stomach, colon, liver, brain, and skin cancers, and,
at lower levels, in some preneoplastic lesions, whereas, it
is repressed in most somatic cells9. There have been sev-
eral studies trying to evaluate TA in melanoma. Studies
were conducted on paraffin embedded tissues and in vi-
tro cells. However, a study using fresh clinical material
was needed to obtain more relevant data. Concerning the
afore mentioned correlation between TA and hTERT ex-
pression real-time PCR measurement of hTERT expres-
sion would provide a more precise insight than outdated
immunohistochemical methods measuring TA. The re-
sults showing that in this data pool dysplastic nevi have
higher hTERT expression than malignant melanoma are
unexpected and contradictory to some former studies
concerning TA and melanoma10. All prior research show-
ing higher TA or hTERT expression in melanomas than
dysplastic nevi include overlapping ranges11. In this study
benign and malignant type also showed overlapping ex-
pression range. However, dysplastic nevi had somewhat
greater hTERT expression than primary melanoma.
Our findings are not in agreement with previous stud-
ies. This could be explained by a small total sample
count, but it can also be explained by the nature of
telomerase. For a gene to be defined as an oncogene, it
needs to have a direct impact on the loss of cell growth
control. Telomerase is responsible for cell immortaliza-
tion but there must be a different trigger for the loss of
growth control, so, telomerase is not an oncogene. Im-
mortalizing cells facilitate the accumulation of muta-
tions12. Thus, immortal cells have more chance to gather
the critical mutation which will trigger cancer formation.
We believe that telomerase cannot be considered a re-
liable diagnostic factor which was also concluded by some
other authors11. Different methods provide different re-
sults that cannot be widely applicable. However, hTERT
and telomerase are enzymes with many functions which
are still undiscovered and need further research.
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REAL-TIME EKSPRESIJA HTERT-A U BIOPSIJAMA PRIMARNOG MELANOMA
S A @ E T A K
Melanom ko`e je najsmrtonosniji me|u tumorima ko`e, po prirodi je nepredvidiv te predstavlja ozbiljan dijagno-
sti~ki problem. Razlikovanje displasti~nog nevusa od malignog melanoma je jedna od najva`nijih stavki u dijagnostici
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melanoma. Cilj ove studije jest evaluacija nivoa ekspresije hTERT-a u razli~itim dermalnim lezijama (od normalne ko`e
do malignog melanoma) te procjena u~inkovitosti hTERT-a kao biomarkera u dijagnostici melanoma. U ovoj studiji smo
analizirali ekspresiju hTERT-a koriste}i Real-time PCR u 58 bioptata svje`eg tkiva (4 uzorka normalne ko`e,12 der-
malnih nevusa, 23 displasti~na nevusa, 19 primarnih melanoma).Na{i rezultati pokazuju ne{to ve}u hTERT ekspresiju
u displasti~nim nevusima nego u melanomima uz veliko preklapanje podataka. S obzirom na dobivene rezultate hTERT
se nije pokazao kao dobar biomarker u dijagnostici melanoma.
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